Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Gyre Therapeutics (GYRE) EPS (Basic) (2016 - 2025)

Gyre Therapeutics (GYRE) has disclosed EPS (Basic) for 16 consecutive years, with -$0.02 as the latest value for Q4 2025.

  • Quarterly EPS (Basic) fell 1619.09% to -$0.02 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $0.05 through Dec 2025, down 64.29% year-over-year, with the annual reading at $0.06 for FY2025, 57.14% down from the prior year.
  • EPS (Basic) for Q4 2025 was -$0.02 at Gyre Therapeutics, down from $0.04 in the prior quarter.
  • The five-year high for EPS (Basic) was $1.64 in Q2 2022, with the low at -$1.54 in Q4 2023.
  • Average EPS (Basic) over 5 years is -$0.22, with a median of $0.0 recorded in 2024.
  • The sharpest move saw EPS (Basic) skyrocketed 356.25% in 2022, then tumbled 1619.09% in 2025.
  • Over 5 years, EPS (Basic) stood at -$0.64 in 2021, then tumbled by 100.0% to -$1.28 in 2022, then decreased by 20.31% to -$1.54 in 2023, then skyrocketed by 99.92% to -$0.0 in 2024, then crashed by 1619.09% to -$0.02 in 2025.
  • According to Business Quant data, EPS (Basic) over the past three periods came in at -$0.02, $0.04, and $0.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.